Gary Nachman

Mallinckrodt PLC (NYSE: MNK) shares have been on an extended downtrend since the middle of 2015. From over $130 in early 2015, the stock is now barely above $1. Much of the downside is attributable to allegations regarding opioid addiction and opioid overdose deaths that implicate not only...

Lannett Company, Inc. (NYSE: LCI) shares rocketed higher by 38% on Wednesday after the company reported a solid fiscal fourth quarter and impressive fiscal 2020 guidance. One Wall Street analyst said the quarter was solid, but investors should remain cautious on Lannett given questions surrounding...

Horizon Therapeutics PLC (NASDAQ: HZNP), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets. The Analyst Gary Nachman upgraded Horizon Therapeutics from Market Perform to Outperform and lifted the price...

Trevi Therapeutics Inc (NASDAQ: TRVI) priced its 5.5 million share IPO at $10 May 7, and shares have been mostly trading at a discount since then. The Analyst Following the expiry of the IPO quiet period, BMO Capital Markets analyst Gary Nachman initiated coverage of shares of Trevi with an...

Mallinckrodt PLC (NYSE: MNK) announced Tuesday that it filed a lawsuit against the Department of Health and Human Services and Centers for Medicare and Medicaid Services, challenging the federal government's decision to have the company change the base date average manufacturer price used to...

Mylan NV (NASDAQ: MYL) reported disappointing fourth-quarter earnings Tuesday and forecast an earnings shortfall for 2019. The Analysts BMO Capital Markets analyst Gary Nachman maintained an Outperform rating on Mylan shares and reduced the price target from $44 to $40. Cantor Fitzgerald...

Lannett Company, Inc. (NYSE: LCI) reported solid second-quarter results Wednesday and raised its 2019 guidance. The pharma company is making good progress in preparing for the loss of levothyroxine with new launches and cost-cutting initiatives, according to BMO Capital Markets. The...

Wall Street firms have given rave reviews for OptiNose Inc (NASDAQ: OPTN), which IPO-ed recently. BMO Capital Markets was no exception, assigning its top rating to shares of the company. The Analyst BMO issued its initiation note on OptiNose on Tuesday, with Gary Nachman being the lead analyst...

Flexion Therapeutics Inc (NASDAQ: FLXN) announced last week it has received regulatory approval for its Zilretta therapy represents a "monumental milestone" for the company, BMO Capital Markets analyst Gary Nachman commented in a research report. The analyst maintains an Outperform rating on...

The latest chapter in the Valeant Pharmaceuticals Intl Inc (NYSE: VRX) drama is a happy one. Shares of the battered pharma stock are up nearly 24 percent this week after the company reported Q1 earnings and raised its full-year earnings guidance. Despite the good news and the positive move,...

Pershing Square announced it has sold its entire stake in Valeant Pharmaceuticals Intl Inc (NYSE: VRX), primarily due to “a disproportionately large amount of time and resources required to manage the investment and a decision to realize a large tax loss and dedicate more time to the rest of...

Gary Nachman of BMO Capital Markets has some good news and bad news for Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s investors following the company's third-quarter earnings report. The good news is that Valeant's new segment reporting could provide greater visibility on its business outlook. The...

BMO Capital’s Gary Nachman believes the recently announced sale of the nuclear imaging business by Mallinckrodt PLC (NYSE: MNK) might be dilutive to the company’s EPS but is likely to be accretive to the company’s overall growth and margins. Nachman reiterated an Outperform rating...

Brean Capital has downgraded Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Hold from Buy after the FDA said it is evaluating adverse event reports of local anesthetic systemic toxicity (LAST) with company's drug Exparel. "We are downgrading Pacirato Hold from Buy for what we believe will amount to...